Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (17)

2023

  1. Disease control in patients with ankylosing spondylitis in real clinical practice in Spain: Results of the MIDAS study

    Reumatologia Clinica, Vol. 19, Núm. 2, pp. 99-105

  2. Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study

    Reumatologia Clinica, Vol. 19, Núm. 4, pp. 204-210

  3. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

2021

  1. One-year, efficacy and safety open label study, with a single injection of a new hyaluronan for knee oa: The soya trial

    Journal of Pain Research, Vol. 14, pp. 2229-2237

2020

  1. "There is something you must see": breaking down the remission concept in rheumatoid arthritis from a rheumatologist's perspective

    Clinical and experimental rheumatology, Vol. 38, Núm. 1, pp. 82-87

  2. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

    Autoimmunity Reviews, Vol. 19, Núm. 1

  3. Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: A protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)

    Trials, Vol. 21, Núm. 1

  4. Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al

    Clinical and experimental rheumatology

2019

  1. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study

    Clinical and experimental rheumatology, Vol. 37, Núm. 3, pp. 437-444

2017

  1. Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: Time for a new approach?

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 5, pp. 816-822

2014

  1. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

2009

  1. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility

    Arthritis Research and Therapy, Vol. 11, Núm. 2

  2. Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, Eotaxin-3, and MHC2TA

    Journal of Rheumatology, Vol. 36, Núm. 8, pp. 1590-1595

  3. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors

    Arthritis and Rheumatism, Vol. 60, Núm. 9, pp. 2558-2564

2006

  1. SLC22A4, RUNX1, and SUMO4 polymorphisms are not associated with rheumatoid arthritis: A case-control study in a Spanish population

    Journal of Rheumatology, Vol. 33, Núm. 7, pp. 1235-1239

2005

  1. Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis

    Human Immunology, Vol. 66, Núm. 8, pp. 864-868

1999

  1. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5

    Arthritis and Rheumatism, Vol. 42, Núm. 5, pp. 989-992